Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

Fig. 1

Decision tree model comparing companion diagnostics in sequence versus NGS. Legend: NSCLC: non-small cell lung cancer; pT+: proportion of positive tests (TP + FP); pT-: proportion of negative results (TN + FN); pTP: true positive probability; pFP: false positive probability; pTN: true negative probability; pFN: false negative probability. Note: pTP = prevalence x sensitivity x (1-unknow); pFP = (1-prevalence) x (1-specificity) x (1-unknow); pTN = (1-prevalence) x specificity x (1-unknow); pFN = prevalence x (1-sensitivity) x (1-unknow)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us